



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C12N 15/83, 15/11, 15/53, 15/52, 5/10, A01H 5/00</b>		A2	(11) International Publication Number: <b>WO 95/34668</b>
			(43) International Publication Date: 21 December 1995 (21.12.95)
(21) International Application Number: PCT/US95/06741		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 26 May 1995 (26.05.95)			
(30) Priority Data: 260,546 16 June 1994 (16.06.94) US			
(71) Applicant: BIOSOURCE TECHNOLOGIES, INC. [US/US]; 3333 Vaca Valley Parkway, Vacaville, CA 95688 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(72) Inventors: KUMAGAI, Monto, H.; 1330 Brown Drive, Davis, CA 95616 (US). DELLA-CIOPPA, Guy, R.; 814 Derry Circle, Vacaville, CA 95688 (US). DONSON, Jonathan; 717 Alvarado Avenue #233, Davis, CA 95616 (US). HARVEY, Damon, A.; 409 Eagle Lane, Vacaville, CA 95687 (US).			
(74) Agents: HALLUIN, Albert, P. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).			
(54) Title: THE CYTOPLASMIC INHIBITION OF GENE EXPRESSION			
(57) Abstract			
<p>One aspect of the invention is to provide novel genetic constructions for the expression of inhibitory RNA in the cytoplasm of eukaryotic cells. The inhibitory RNA may be an anti-sense RNA or a co-suppressor RNA. The genetic constructions of the invention are capable of replicating in the cytoplasm of a eukaryotic cell and comprise a promoter region in functional combination with an encoding polynucleotide. The genetic constructions may be designed so as to replicate in the cytoplasm of plant cells, yeast cells, and mammalian cells. When the eukaryotic cell of interest is a plant cell, the genetic construction is preferably derived from a plant RNA virus. Plant RNA virus derived genetic constructions may employ a plant virus subgenomic promoter, including subgenomic promoters from tobamoviruses in functional combination with the RNA encoding region. Another aspect of the invention is to provide cells comprising the genetic constructions of the invention and organism comprising a plurality of such cells. Another aspect of the invention is to provide methods of reducing the expression of a gene of interest in eukaryotic cells, i.e., methods of producing eukaryotic cells exhibiting reduced levels of expression of a gene of interest. The methods of the invention comprise the step of transfecting a cell with a genetic construction of the invention in which the RNA encoding region is specific for the gene of interest. Another aspect of the invention is to provide plant cells that produce elevated levels of the carotenoid phytoene. The elevated levels of phytoene are achieved by inhibiting the expression at the enzyme phytoene desaturase using the vectors of the invention.</p>			
<p>.lsp XbaI Start codon  <u>GT</u><u>TAA</u><u>ATACCCCGGTTTAAAT</u> ATG TCT GTT CCC TTG TTA TCC GTT TTG TCT CCT TGT GAC  Met Ser Val Ala Leu Leu Trp Val Val Ser Pro Cys Asp</p> <p>TRANSIT PEPTIDE OF PHYTOENE SYNTHASE  CTC TCA AAT CGG ACA AGT TTC ATG GAA TCA GTC CGG GAG CGA AAC CGT  Val Ser Asn Gly Thr Ser Phe Met Glu Ser Val Arg Glu Gly Asn Arg</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**THE CYTOPLASMIC INHIBITION OF  
GENE EXPRESSION**

5    **FIELD OF THE INVENTION**

This invention is in the field of gene regulation through anti-sense RNA endogenously produced inhibitory RNA molecules such as anti-sense RNA and co-suppressor RNA.

10

**BACKGROUND**

One of the primary goals of genetic engineering has been to control the expression of selected genes in eukaryotic organisms of interest. While it has 15 been relatively straightforward to insert new genes for expression into eukaryotic cells, the targeting of endogenous genes for reduced expression has been more difficult to achieve. Site-directed inactivation of genes in higher organisms has required extremely complex genetic manipulations and is not applicable to a wide range of organisms. One method reducing the expression 20 of specific genes in eukaryotic organisms has been through the use of anti-sense RNA and through co-suppression.

Anti-sense RNA has been used to reduce the expression of pre-selected 25 genes in both plants and animals. Descriptions of the use of anti-sense RNA to reduce the expression of selected genes in plants can be found, among other places in U.S. patent 5,107,065, Smith *et al.* *Nature* 334: 724-726 (1988), Van der Krol *et al.*, *Nature* 333: 866-869 (1988), Rothstein *et al.*, *Proc. Natl. Acad. Sci. USA* 84:8439-8443 (1987), Bird *et al.*, *Bio/Technology* 9:635-639 30 (1991), Bartley *et al.* *Biol. Chem.* 267:5036-5039 (1992), and Gray *et al.*, *Plant Mol. Bio.* 19:69-87 (1992).

Another method of reducing the expression of specific genes in eukaryotic organisms is through the use of co-suppressor RNA. Co-

35

suppressor RNA, in contrast to anti-sense RNA, is in the same orientation as the RNA transcribed from the target gene, i.e., the "sense" orientation.

It is possible that biochemical pathways in plants transfected with hybrid viruses could be altered by overproducing an enzyme involved in a rate-limiting step, or by inhibiting the synthesis of an enzyme via antisense RNA. Although the expression of numerous genes in transgenic plants have been repressed by antisense RNA, the actual mechanism and location of inhibition is not known. In the nucleus, antisense RNA may directly interfere with transcription or form duplexes with the heterogenous nuclear (hnRNA). There is evidence that inhibition of endogenous genes can occur in transgenic plants containing sense RNA A.R. van der Krol *et al.*, *Nature* 333:866-869 (1988) and C. Napoli *et al.*, *Plant Cell* 2:279-289 (1990)

mechanism of this down regulation or "co-suppression" is thought to be caused by the production of antisense RNA by read through transcription from distal promoters located on the opposite strand of the chromosomal DNA (Greison, *et al.* *Trends in Biotech.* 9:122-123 (1991)). Alternatively, in the cytoplasm, antisense RNA may form a double-stranded molecule with the complimentary mRNA and prevent the translation of mRNA into protein.

Tobamoviruses, whose genomes consist of one plus-sense RNA strand of approximately 6.4 kb, replicate solely in the cytoplasm, and can be used as episomal RNA vectors to alter plant biochemical pathways. Hybrid tobacco mosaic (TMV)/ odontoglossum ringspot viruses (ORSV) have been used previously to express heterologous enzymes in transfected plants (Donson, *et al.* *Proc. Natl. Aca. Sci. USA* 88:7204 (1991) and Kumagai, *et al.* *Proc. Natl. Aca. Sci USA* 90:427-430 (1993), minus-Sense RNA Strand, (Miller, *et al.*). Infectious RNA transcripts from viral cDNA clones encode proteins involved in RNA replication, movement, and encapsidation (10). Subgenomic RNA for messenger RNA synthesis is controlled by internal promoters located on the minus-sense RNA strand (*N. benthamiana* plants were inoculated with *in vitro* transcripts as described previously [W.O. Dawson, *et al.*, *Proc.*

*Natl. Acad. Sci. U.S.A.* 83, 1832 (1986)]. Insertion of foreign genes into a specific location under the control of an additional subgenomic RNA promoter have resulted in systemic and stable expression of neomycin phosphotransferase and  $\alpha$ -trichosanthin (Donson, *et al.* *Proc. Natl. Acad. Sci. USA* 88:7204 (1991) and Kumagai, *et al.* *Proc. Natl. Acad. Sci. USA* 90:427-430 (1993)).

One of the many biochemical pathways that could serve as a target for genetic manipulation is the biosynthesis of carotenoids. On the first committed step in carotenoid biosynthesis in higher plants is the condensation of two geranylgeranyl pyrophosphate molecules to phytoene, a colorless C<sub>40</sub> hydrocarbon, by the enzyme phytoene synthase. In the ripening fruit of *Lycopersicon esculentum*, phytoene synthase is a monomeric, chloroplast localized protein with an approximate relative molecular mass of 42 kDa. This enzyme is initially synthesized as a 47-kDa preprotein and is processed by the removal of a transit peptide during import to the chloroplast (Bartley, *et al.* *J. Biol. Chem.* 267:5036-5039 (1992)). Transgenic tomato plants containing anti-sense to phytoene synthase mRNA produce yellow fruit and pale flowers. Although the fruit specific carotenes are reduced by 97%, the levels of carotenoids in the leaves of the transgenic plants are unaffected, (Bird, *et al.*, *Bio/Technology* 9:635-639 (1991)). It has been proposed that an additional set of biosynthetic genes occurs in plants which regulate the expression of leaf specific carotenoids.

The subsequent step in the biosynthetic pathway is the modification of the colorless phytoene to phytofluene and  $\zeta$ -carotene by phytoene desaturase. Among higher plants, the isolation of gene encoding this enzyme has been described for tomato, Pecker, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 89, 4962 (1992), and *Arabidopsis thaliana* (Scolnick and Bartley, *Plant Physiol* 103:147 (1993)). Phytoene desaturase is inhibited by norflurazon, a bleaching herbicide, in a reversible, non-competitive manner (Sandman, *et al.*, *Target Sites of Herbicide Actions*, G. Sandman, P. Boger Es. (RC press, Boca Rotan

(1989)). Application of this compound causes a dramatic decrease in leaf carotenoids and chlorophylls and a subsequent accumulation of phytoene. The reduction of the photoprotective carotenoids derived from phytoene may cause 5 a rapid destruction of chlorophyll by photooxidation.

The need for new methods of reducing the expression of specific genes in eukaryotes is clearly established. The invention described herein provides 10 new methods for reducing the expression of selected genes, genetic constructions for practicing the methods, and cells transformed by these genetic constructions, and higher organisms comprising the transformed cells.

### **SUMMARY OF THE INVENTION**

One aspect of the invention is to provide novel genetic constructions 15 for the expression of inhibitory RNA in the cytoplasm of eukaryotic cells. The genetic constructions of the invention are capable of replicating in the cytoplasm of a eukaryotic cell and comprise a promoter region in functional combination with an inhibitory RNA encoding polynucleotide, i.e., encoding 20 an anti-sense RNA or a co-suppressor RNA. The genetic constructions of the invention may be designed so as to replicate in the cytoplasm of plant cells, yeast cells, or mammalian cells. When the eukaryotic cell of interest is a plant cell, the genetic construction is preferably derived from a plant RNA virus, more preferably a positive single-stranded RNA virus. Plant RNA 25 virus derived genetic constructions may comprise a plant virus subgenomic promoter, including subgenomic promoters from tobamoviruses, in functional combination with the inhibitory RNA encoding region.

Another aspect of the invention is to provide cells comprising the 30 genetic constructions of the invention and to provide organisms comprising a plurality of such cells.

Another aspect of the invention is to provide methods of reducing the expression of a gene of interest in eukaryotic cells, i.e., methods of producing 35 eukaryotic cells exhibiting reduced levels of expression of a gene of interest.

The methods of the invention comprise the step of transforming a cell with a genetic construction of the invention in which the inhibitory RNA encoding region is specific for the gene of interest. Another aspect of the invention is to provide plant cells that produce elevated levels of the carotenoid phytoene.

5 The elevated levels of phytoene are achieved by inhibiting the expression at the enzyme phytoene desaturase using the vectors of the invention.

#### BRIEF DESCRIPTION OF THE FIGURES

10 **Fig. 1.** Phytoene expression vector TTO1/PSY+. This plasmid contains the TMV-U1 126-, 183-, and 30-kDa ORFs, the ToMV coat protein gene (ToMVcp), the SP6 promoter, the tomato phytoene synthase gene, and part of the pBR322 plasmid. The TAA stop codon in the 30-kDa ORF is underlined.

15 The TMV-U1 subgenomic promoter located within the minus strand of the 30-kDa ORF controls the expression of phytoene synthase. The putative transcription start point (tsp) of the subgenomic RNA is indicated with a period (.).

20 **Fig. 2.** Nucleotide sequence comparison of *N. benthamiana* leaf phytoene desaturase (*PDS1-Nb*) and tomato phytoene desaturase (*PDS-Le*). The nucleotides are aligned to maximize sequence similarity.

25

30

35

## DESCRIPTION OF THE SPECIFIC EMBODIMENTS

### Definitions

The term "inhibitory RNA", as used herein, refers to an RNA molecule that interferes with the expression of a target gene. An "inhibitory RNA" is specific for one or more target genes. An inhibitory RNA may be an anti-sense RNA with respect to an RNA molecule transcribed from the target gene. Alternatively, the target gene inhibitory RNA may be a co-suppressor RNA with respect to an RNA molecule transcribed from the target gene.

The term "anti-sense RNA" as used herein, refers to an RNA molecule that is capable of forming a duplex with a second RNA molecule. Thus a given RNA molecule is said to be an anti-sense RNA molecule with respect to a second, complementary or partially complementary RNA molecule, i.e., the target molecule. An anti-sense RNA molecule may be complementary to a translated or an untranslated region of a target RNA molecule. The anti-sense RNA need not be perfectly complementary, to the target RNA. Anti-sense RNA may or may not be the same length of the target molecule; the anti-sense RNA molecule may be either longer or shorter than the target molecule.

The term "co-suppressor RNA" refers to an RNA molecule that effects suppression of expression of a target gene where the RNA is partially homologous to an RNA molecule transcribed from the target gene. A co-suppressor RNA molecule is the RNA molecule that effects co-suppression as described in U.S. patent 5,231,020, Krol *et al.*, *Biotechniques* 6:958-976 (1988), Mol *et al.*, *FEBS Lett.* 268:427-430 (1990), and Grierson, *et al.*, *Trends in Biotech.* 9:122-123 (1991) and similar publications. A "co-suppressor" RNA is in the sense orientation with respect to the target gene, i.e., the opposite orientation of the anti-sense orientation.

The term "inhibitory RNA encoding polynucleotide" as used herein, refers to a polynucleotide, e.g., DNA, RNA, and the like, capable of being transcribed, when in functional combination with a promoter, so as to produce

an inhibitory RNA molecule, e.g., an anti-sense RNA or a co-suppressor RNA.

Anti-sense RNA encoding polynucleotides and co-suppressor encoding polynucleotides are both embodiments of the inhibitory RNA encoding polynucleotides. When the inhibitory RNA is an anti-sense RNA, the inhibitory RNA transcribed from the inhibitory RNA encoding polynucleotide region of the genetic constructions of the invention is preferably perfectly complementary to the entire length of the RNA molecule or molecules for which the anti-sense RNA is specific, i.e., the target. The anti-sense RNA encoding polynucleotide in the subject vectors may encode an anti-sense RNA that forms a duplex with a non-translated region of an RNA transcript such as an intron region, or 5' untranslated region, a 3' untranslated region, and the like. Similarly, a co-suppressor encoding polynucleotide in the subject vectors may encode an RNA that is homologous to translated or untranslated portions of a target RNA. An anti-sense RNA encoding polynucleotides may be conveniently produced by using the non-coding strand, or a portion thereof, of a DNA sequence encoding a protein of interest.

The term "reduced expression," as used herein, is a relative term that refers to the level of expression of a given gene in a cell produced or modified by the claimed methods as compared with a comparable unmodified cell, i.e., a cell lacking the subject vector, under a similar set of environmental conditions. Thus, a cell modified by the subject methods, i.e., a cell having "reduced expression" of the gene of interest, may express higher levels of that gene under a first set of environmental conditions, than a comparable unmodified cell under a second set of environmental conditions, if the second set of conditions is highly favorable to gene expression.

30

### The Invention

The invention described herein exploits the discovery that RNA can reduce the expression of a target gene through inhibitory RNA interactions with target mRNA that take place in the cytoplasm of a eukaryotic cell, rather

35

than in the nucleus. Prior to the invention, it was not known if inhibitory RNA reduced gene expression by means of an interaction that takes place in the cytoplasm or an interaction that takes place in the nucleus. Thus, prior to the invention, it was necessary to produce inhibitory RNA in the nucleus so as to be certain that inhibition would be achieved. Furthermore, it was not known if adequate concentrations of inhibitory RNA could be provided in the cytoplasm. Cytoplasmic expression of inhibitory RNA (specific for target genes) has numerous advantages over nuclear expression, these advantages include the ability to use high level expression vectors that are not suitable for nuclear expression. The use of such vectors is particularly advantageous in plants, because vectors capable of systemically infecting plants may be used to produce the inhibitory RNA. The invention described herein has many aspects. These aspects include novel genetic constructions for the expression of target gene inhibitory RNA in the cytoplasm of eukaryotic cells, cells transfected with these genetic constructions, multicellular organisms comprising the transfected cells, and methods for reducing the expression of selected genes in a cell by transforming a cell with a genetic construction of the invention.

There are numerous ways to produce the genetic constructions of the invention. Techniques for manipulating polynucleotides, e.g., restriction endonuclease digestion and ligation, are well known to the person of ordinary skill in the art. These conventional polynucleotide manipulation techniques may be used to produce and use the genetic construction of the invention. While some optimization of standard techniques may be employed to produce the subject genetic constructions, significant experimentation is not required to produce the genetic constructions or practice the claimed methods.

The genetic constructions of the invention comprise a promoter region in functional combination with an inhibitory RNA encoding polynucleotide. The promoter region is selected so as to be capable of driving the transcription of a polynucleotide sequence in a host cell of interest. Thus for example,

when the eukaryotic cell is a plant cell, the promoter is selected so as to be able to drive transcription in plant cells. Promoters capable of functioning in a given eukaryotic cell are well known to the person of ordinary skill in the art. Examples of promoters capable of driving transcription in a cell of interest can be found, among other places in, Goeddel *et al.*, *Gene Expression Technology Methods in Enzymology* Volume 185, Academic Press, San Diego, (1991), Ausubel *et al.*, *Protocols in Molecular Biology*, Wiley Interscience (1994), and similar publications. When the cell for transformation is a plant cell, the RNA virus subgenomic promoters are preferably used as promoter regions. RNA virus subgenomic promoter are described, among other places in Dawson and Lehto, *Advances in Virus Research*, 38:307-342, PCT published application WO93/03161.

The genetic constructions of the invention are capable of replication or maintenance, at least transiently, in the cytoplasm of eukaryotic cells of interest i.e., a base vector. Thus, the genetic constructions of the invention necessarily comprise a polynucleotide region derived from a vector capable of being replicated or stably maintained in eukaryotic cell of interest. Many vectors capable of replication (or stable maintenance) in different types of eukaryotic cells are known. For example, vectors for use in yeast cells include  $2\mu$  circle derived vectors. Information describing vectors yeast and their use in yeast can be found, among other places, in Goeddel, *et al. supra*, Ausubel *et al.*, *supra*, and similar publications.

Vectors for use in mammalian cells include bovine papilloma virus derived vectors, vaccinia derived vectors, semiliki forrest virus vectors and the like. Information describing mammalian cell vectors and their use in mammalian cells can be found, among other places is Goedd, *et al. supra*, and Ausubel *et al.*, *supra*. Vectors for use in plants include vectors derived from cauliflower mosaic virus, tobacco mosaic virus, tomato mosaic virus, and the like. Information describing plant cell vectors and their use in plant cells can

be found, among other places, in PCT application WO93/03161, and Donson, *et al. Proc. Natl. Acad. Sci. USA*, 88:7204-7208 (1991).

The promoter driving transcription of the inhibitory RNA encoding region of the subject genetic constructions may be selected so as have a level of transcriptional activity sufficient to achieve the desired degree of expression of the target gene inhibitory RNA of interest. The promoter may be native or heterologous to the cell for genetic modification. The promoter may also be native or heterologous to the base vector, i.e., the portion of the vector other than the promoter and the inhibitory RNA encoding region. The promoter may be inducible or constitutive. Preferably, strong promoters are used to drive transcription of the inhibitory RNA encoding polynucleotide when the target RNA is highly expressed.

The invention also provides methods of reducing the expression of a gene or genes of interest in a eukaryotic cell. As a consequence of providing the subject methods of reducing gene expression in eukaryotic cell, the subject invention also provides methods of producing a eukaryotic cell having reduced expression of a gene of interest and eukaryotic cells that have reduced expression of a gene of interest, as produced by the methods of the invention. Reduction of gene expression is achieved by introducing one or more of the vectors of the invention into a eukaryotic cell. The vector used to transform the cell of interest comprises an inhibitory RNA encoding polynucleotide that encodes an inhibitory RNA specific for the gene for which reduced expression is sought. The method of reducing expression of the gene of interest comprises the step of introducing the subject genetic vector into a host cell that is capable of expressing the gene of interest under certain environmental conditions. The vector may be introduced into a cell of interest by any of a variety of well known transformation methods. Such methods include: infection, transfection, electroporation, ballistic projectile transformation, conjugation, and the like. The inventive aspect of the subject methods is not dependent upon the particular means by which the inhibitory RNA encoding

vector is introduced into the cell of interest. The particular methods of introducing the vector into a cell of interest is, in part, dependent upon the particular cell for modification and the precise type of vector selected.

When the eukaryotic cells of interest for genetic modification by the subject vectors are plant cells, the vectors are preferably derived from RNA plant viruses. Preferred RNA plant virus vectors are positive strand single stranded RNA viruses. RNA plant virus vectors may be conveniently manipulated and introduced into cells in a DNA form instead of working directly with RNA vectors. Viral vector derived from tobamoviruses are particularly preferred. Descriptions of suitable plant virus vectors that may be modified so as to contain an inhibitory RNA encoding region in functional combination with a promoter as well as how to make and use such vectors, can be found in, among other places, PCT publication WO 93/03161, Kumagai *et al*, *Proc. Natl. Aca. Sci. USA* 90:427-430 (1993).

The invention also provides polynucleotides encoding phytoene synthase and phytoene desaturase, as well as various vector for the expression of target gene inhibitory RNA specific for phytoene synthase genes or phytoene desaturase genes. The first committed step in carotenoid biosynthesis in higher plants is the condensation of two geranylgeranyl pyrophosphate molecules to phytoene, a colorless C<sub>40</sub> hydrocarbon, by the enzyme phytoene synthase. The subsequent step in the biosynthetic pathway is the modification of the colorless phytoene to phytofluene and  $\zeta$ -carotene by phytoene desaturase.

The invention provides polynucleotides encoding the phytoene desaturase enzyme from *Nicotiana* species and numerous derivatives thereof. Specifically, the invention provides, in purified form, polynucleotides encoding the phytoene desaturase of *Nicotiana benthamiana*. Additionally, the invention provides polynucleotides encoding tomato (*Lycopersicon esculentum*) phytoene synthase and phytoene desaturase. The phytoene synthase and phytoene desaturase encoding polynucleotides described herein may be used to

produce inhibitory RNAs specific for phytoene synthase and phytoene desaturase genes from a variety of plant species. The phytoene synthase and phytoene desaturase inhibitory RNA are preferably produced by transcription of phytoene synthase or phytoene desaturase inhibitory RNA encoding polynucleotides in functional combination with a promoter region.

The amino acid sequence of the various phytoene desaturase and the phytoene synthase enzymes described herein and the naturally occurring polynucleotide sequences encoding these enzymes enable a person of ordinary skill in the art of molecular biology to design and construct a variety of related molecules having useful properties similar to these enzymes and the polynucleotides obtained directly from the cloning of the cDNAs encoding these enzymes. In the case of polynucleotides, the degeneracy of the genetic code permits the person of ordinary skill in the art to produce numerous different polynucleotides encoding the same polypeptide, i.e., isocoding polynucleotides. The precise polynucleotide sequence produced may be selected so as to optimize expression in a particular host cell type, taking into account factors affecting expression such as codon frequency, potential mRNA secondary structures, methylation, and the like. The invention also provides a variety of polypeptides having the same enzymatic activity as phytoene desaturase and phytoene synthase, but differing in one or more amino acid residues, so as to produce a phytoene desaturase and phytoene synthase variant polypeptides. Variant polypeptides may be produced and designed in a wide variety of ways. Phytoene desaturase and phytoene synthase variants may be produced and designed by introducing mutations (either random or by design) into a polynucleotide sequence encoding the enzyme, transforming the mutated enzyme encoding polynucleotide (operably linked to a suitable promoter) into a host cell, and subsequently assaying the host cell for the expression of the desired enzymatic activity. The identity of mutations in Srf I encoding polynucleotides introduced randomly, may be determined by sequencing the polynucleotide encoding the enzyme.

The invention also provides for the recombinant DNA expression of phytoene desaturase adn phytoene synthase (as well as variants thereof). The recombinant expression of these enzyme may be achieved through standard recombinant DNA expression technology. Suitable recombinant DNA expression technology can be found, among other places, in Goeddel, *et al.*, *Gene Expression Technology: Methods in Enzymology Volume 185* Academic Press, San Diego (1991). The enzyme may be expressed in a wide range of host cells, including both eukaryotic and prokaryotic host cells. One advantage of providing the subject enzymes by recombinant DNA methodology is the production of increased amounts of enzyme from reduced amounts of cellular material.

Another advantage of the recombinant production of the enzymes is the ability to produce the enzyme free of certain contaminants. Phytoene synthase and phytoene desaturase (and variants thereof) produced by recombinant DNA techniques may be purified by procedures similar to the procedures described herein for the purification of the non-recombinant enzyme. Guidance in devising and modifying enzyme purification procedures can be found, among other places in Deutscher *Guide to Protein Purification Methods in Enzymology - Volume 182* Academic Press, San Diego (1990), Scopes *Protein Purification: Principles and Practice* 3rd edition Springer-Verlag, NY (1993), and the like.

The invention may be better understood by referring to the following examples. The following examples are offered for the purpose of illustrating the invention and should not be interpreted as a limitation of the invention.

30

35

EXAMPLESExample 1Isolation of tomato mosaic virus cDNA.

5 An 861 bp fragment (5524-6384) from the tomato mosaic virus (fruit necrosis strain F; ToMV-F) containing the putative coat protein subgenomic promoter, coat protein gene, and the 3' end was isolated by PCR using ToMV primers 5' CTCGCAAAGTTCGAACCAAATCCTC 3' (SEQ ID NO: 1) (upstream) and 5' CGGGGTACCTGGGCCCAACCGGGGGTCCGGGGG3' (SEQ ID NO:2) (downstream) and subcloned into the *Hinc*II site of pBluescript KS-. A hybrid virus consisting of TMV-U1 and ToMV-F was constructed by swapping an 874-bp *Xho*I-*Kpn*I ToMV fragment into pBGC152 (Kumagai, et al. *Proc. Natl. Acad. Sci USA*, 90:427-430 (1993)), creating plasmid TTO1. The inserted fragment was verified by dideoxynucleotide sequencing. A unique *Avr*II site was inserted downstream of the *Xho*I site in TTO1 by PCR mutagenesis, creating plasmid TTO1A, using the following oligonucleotides:

10 20 25

5' TCCTCGAGCCTAGGCTCGCAAAGTTCGAACCAAATCCTCA 3'  
(SEQ ID NO:3) (upstream),  
5' CGGGGTACCTGGGCCCAACCGGGGGTCCGGGGG 3' (SEQ ID NO:2) (downstream).

25

Example 2Isolation of a cDNA encoding tomato phytoene synthase and a partial cDNA encoding tomato phytoene desaturase.

30 Partial cDNAs were isolated from ripening tomato fruit RNA by polymerase chain reaction (PCR) using the following oligonucleotides: *PSY*, 5' TATGTATGGTGCAGAAGAACAGAT 3' (SEQ ID NO:4) (upstream), 5' AGTCGACTCTCCTCTTCTGGCATC 3' (SEQ ID NO:5) (downstream);  
35 *PDS*, 5' TGCTCGAGTGTGTTCTCAGTTCTGTCA 3' (SEQ ID NO:6)

(upstream), 5' AACTCGAGCGCTTGATTCTCCGAAGCTT 3' (SEQ ID NO: 7) (downstream). Approximately 3 X 10<sup>4</sup> colonies from a *Lycopersicon esculentum* cDNA library were screened by colony hybridization using a 32 P labelled tomato phytoene synthase PCR product. Hybridization was carried out at 42°C for 48 h in 50% formamide, 5X SSC, 0.02 M phosphate buffer, 5X Denhart's solution, and 0.1 mg/ml sheared calf thymus DNA. Filters were washed at 65°C in 0.1X SSC, 0.1% SDS prior to autoradiography. PCR products and the phytoene synthase cDNA clones were verified by dideoxynucleotide sequencing.

### Example 3

#### DNA sequencing and computer analysis.

A 1.2 Kb PstI , BamHI fragment containing the phytoene synthase cDNA and a .7 Kb the partial phytoene desaturase cDNA was subcloned into pBluescript KS+ (Stratagene, La Jolla, Calif.). The nucleotide sequencing of KS+/PDS #38 and KS+/ 5'3'PSY was carried out by dideoxy termination using single stranded templates. Nucleotide sequence analysis and amino acid sequence comparisons were performed using PCGENE and DNA Inspector IIE programs.

### Example 4

#### Construction of the tomato phytoene synthase expression vector.

A 1253 base pair *Xho*I fragment containing the tomato phytoene synthase cDNA was subcloned into TTO1. The vector TTO1/PSY+ (Fig.1) contains the phytoene synthase cDNA (positive orientation) under the control of the TMV-U1 coat protein subgenomic promoter; while, the vector TTO1/PSY - contains the phytoene synthase cDNA in the anti-sense orientation.

Example 5Construction of a viral vector containing a partial tomato phytoene desaturase cDNA.

5 An *Xba*I fragment containing the partial tomato phytoene desaturase cDNA was subcloned into TTO1. The vector TTO1A/PDS+ contains the phytoene desaturase cDNA (positive orientation) under the control of the TMV-U1 coat protein subgenomic promoter; while, the vector TTO1/PDS- contains the phytoene desaturase cDNA in the antisense orientation.

10 A partial cDNA encoding phytoene desaturase was isolated from *N. benthamiana* leaf RNA by RT-PCR using the following oligonucleotides: *PDS*, 5' GGCACTCAACTTATAAACCC 3' (SEQ ID NO:8) (upstream), 5' CTTCAGTTTCTGTCAAACC 3' (SEQ ID NO:9) (downstream) and verified  
15 by dideoxynucleotide sequencing.

Example 6Transfection and analysis of *N. benthamiana* [TTO1/PSY+, TTO1/PSY-,TTO1/PDS700 +, TTO1/PDS700 -].

20 Infectious RNAs from TTO1/PSY+ (Fig. 1), TTO1/PSY-, TTO1A/PDS+, TTO1/PDS- were prepared by *in vitro* transcription using SP6 DNA-dependent RNA polymerase and were used to mechanically inoculate *N. benthamiana* (Dawson, *et al.*, *Adv. Virus Res.* 38:307 (1990)). The hybrid  
25 viruses spread throughout all the non-inoculated upper leaves as verified by transmission electron microscopy, local lesion infectivity assay, and polymerase chain reaction (PCR) amplification. The viral symptoms consisted of distortion of systemic leaves, plant stunting, and mild chlorosis. Plants  
30 transfected with TTO1/PSY+ showed at least a two fold increase in phytoene synthase activity over plants transfected with viral vector controls. Leaves from systemically infected TTO1/PSY+ plants developed a bright orange phenotype and accumulated high levels of phytoene (Table 1). The leaves and  
35 sepals from TTO1/PDS- plants developed a white bleaching phenotype similar

to that seen with the herbicide norflurazon. The structure of the chloroplasts from TTO1/PSY+ and TTO1/PDS- transfected plants, when analyzed by transmission electron microscopy, appeared to be normal. Leaves from systemically infected TTO1A/PDS+ plants developed a bleaching white phenotype approximately one week later than leaves from antisense TTO1/PDS- plants and also accumulated high levels of phytoene.

Agarose gel electrophoresis of PCR cDNA isolated from virion RNA and Northern blot analysis of virion RNA indicate that the vectors are maintained in an extrachromosomal state and have not undergone any detectable intramolecular rearrangements.

Table I.

Quantitation of phytoene leaves of *N. benthamiana* transfected with viral transcripts.

	<u>Plant</u>	<u>Phytoene µg/g FW</u>	<u>fold increase</u>
20	<i>N. benthamiana</i> -----	4.6	1
	<i>N. benthamiana</i> : TTO1/PDS-	234.8	51.0
	<i>N. benthamiana</i> : Norflurozon	339.8	73.9
	<i>N. benthamiana</i> : TTO1/PSY+	52.4	11.4
25	<i>N. benthamiana</i> : TTO1/PSY-	1.0	0.2

Example 7

Purification and analysis of phytoene from transfected plants

Phytoene was extracted in methanol and identified by its peak retention time and absorption spectra on a 25-cm Spherisorb ODS-1 5-µm column using acetonitrile/ methanol/ 2-propanol (85:10:5) as a developing solvent at a flow rate of 1 ml/ min. The phytoene isolated from systemically infected tissue had an identical retention time to phytoene from norflurozon treated plants.

35 The phytoene peak from *N. benthamiana* transfected with TTO1/PSY+ had a

characteristic optical absorbance maxima at 276, 285, and 298 nm. One week after inoculation, plants transfected with viral encoded phytoene synthase showed a hundred-fold increase in phytoene compared to the levels in noninfected plants as measured by HPLC separation of carotenoids. The carotenoids were extracted in methanol and identified by their peak retention time and absorption spectra on a 25-cm Spherisorb ODS-1 5- $\mu$ m column using acetonitrile/methanol/2-propanol (85:10:5) as a developing solvent. The expression of sense (TTO1A/PDS+) and antisense (TTO1/PDS-) RNA to a partial phytoene desaturase in transfected plants inhibited the synthesis of colored carotenoids and caused the systemically infected leaves to develop a white phenotype. HPLC analysis of these plants revealed that they also accumulated phytoene high levels. The bleaching of leaves was reproduced in control plants treated with the herbicide norflurozon, a non-competitive inhibitor of phytoene desaturase.

#### Example 8

20 **Isolation of a partial cDNA encoding *N. benthamiana* phytoene desaturase.**

A partial cDNA clone that encodes for *N. benthamiana* phytoene desaturase was isolated from young leaf tissue. Nucleotide sequence comparison of 369 bp in the corresponding regions between tomato and *N. benthamiana* phytoene desaturase indicate that they are 92% similar to each other (Fig. 2). Since the two plant genes have areas of high homology, cytoplasmic inhibition of the endogenous plant gene by viral-derived antisense RNA may occur through the formation of hybrid, double stranded RNA molecules. The down regulation of phytoene desaturase in plants transfected with TTO1A/PDS+ may be caused by direct interference during the translation of mRNA into protein or by duplexes formed between mRNA and viral-derived negative strand RNA, although the precise mechanism of action does not need to be known to carry out the invention.

**Example 9****Construction of TTO1 and TTO1A expression vectors**

An 861 bp fragment (5524-6384) from the tomato mosaic virus (fruit necrosis strain F; ToMV-F) containing the putative coat protein subgenomic promoter, 5 coat protein gene, and the 3' end was isolated by PCR using ToMV primers 5' CTCGCAAAGTTCGAACCAAATCCTC 3' (SEQ ID NO:1) (upstream) and 5' CGGGGTACCTGGGCCCAACCGGGGGTTCCGGGG 3'(SEQ ID NO:2) (downstream) and subcloned into the *Hinc*II site of pBluescript KS-. A 10 hybrid virus consisting of TMV-U1 and ToMV-F was constructed by swapping an 874-bp *Xho*I-*Kpn*I ToMV fragment into pBGC152 (I. Pecker, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 89, 4962 (1992)), creating plasmid TTO1. The inserted fragment was verified by dideoxynucleotide sequencing. A 15 unique *Avr*II site was inserted downstream of the *Xho*I site in TTO1 by PCR mutagenesis, creating plasmid TTO1A, using the following oligonucleotides: 5' TCCTCGAGCCTAGGCTCGCAAAGTTCGAACCAAATCCTCA 3' (upstream) (SEQ ID NO:3), 20 5' CGGGGTACCTGGGCCCAACCGGGGGTTCCGGGG 3' (SEQ ID NO: 2) (downstream).

**Example 10****Construction of TTO1/PDS-, TTO1A/PDS+**

25 Using PCR mutagenesis a *Xho*I fragment, encoding tomato phytene synthase was amplified from a *Lycopersicon esculentum* cDNA clone isolated from a ripening fruit cDNA library, and placed under the control of the TMV-U1 coat protein subgenomic promoter by subcloning into TTO1.

30

35

**Example 11**

**Inhibition of the expression of a specific endogenous plant gene (phytoene desaturase) using an RNA viral vector: Transfection and analysis of *N. benthamiana* [TTO1/PDS-, TTO1A/PDS+]**

5 Infectious RNAs from TTO1A/PDS+, TTO1/PDS- were prepared by *in vitro* transcription using SP6 DNA-dependent RNA polymerase and were used to mechanically inoculate *N. benthamiana*. The hybrid viruses spread throughout all the non-inoculated upper leaves as verified by transmission electron microscopy, local lesion infectivity assay, and polymerase chain reaction (PCR) amplification. The viral symptoms consisted of distortion of systemic leaves, plant stunting, and mild chlorosis. The leaves and sepals from TTO1/PDS- plants developed a white bleaching phenotype similar to that  
10 seen with the herbicide norflurazon. The structure of the chloroplasts from TTO1/PDS- transfected plants, when analyzed by transmission electron microscopy, appeared to be normal. Leaves from systemically infected TTO1A/PDS+ plants developed a bleaching white phenotype approximately  
15 one week later than leaves from antisense TTO1/PDS plants and also  
20 accumulated high levels of phytoene.

**Example 12**

25 **Inhibition of the expression of a specific endogenous plant gene (phytoene synthase) using an RNA viral vector: Transfection and analysis of *N. benthamiana* [TTO1/PSY-]**

30 Infectious RNAs from TTO1/PSY- were prepared by *in vitro* transcription using SP6 DNA-dependent RNA polymerase and were used to mechanically inoculate *N. benthamiana*. The hybrid viruses spread throughout all the non-inoculated upper leaves as verified by transmission electron microscopy, local lesion infectivity assay, and polymerase chain reaction  
35 (PCR) amplification. The viral symptoms consisted of distortion of systemic

leaves, plant stunting, and mild chlorosis. Plants transfected with TTO1/PSY+ showed at least a two fold increase in phytoene synthase activity over plants transfected with viral vector controls (data not shown). Leaves from systemically infected TTO1/PSY+ plants developed a bright orange phenotype and accumulated high levels of phytoene (Table 1). The leaves from TTO1/PDS- plants developed a light bleaching phenotype. The structure of the chloroplasts from TTO1/PSY- when analyzed by transmission electron microscopy, appeared to be normal. Leaves from systemically infected TTO1A/PSY- plants did not accumulate phytoene.

**Example 13**

**Isolation of a partial cDNA encoding *N. benthamiana* phytoene desaturase**

A partial cDNA clone that encodes for *N. benthamiana* phytoene desaturase was isolated from young leaf tissue. Nucleotide sequence comparison of 380 bp in the corresponding regions between tomato and *N. benthamiana* phytoene desaturase indicate that they are 92% similar to each other (figure 2). Since the two plant genes have areas of high homology, cytoplasmic inhibition of the endogenous plant gene by viral-derived antisense RNA may occur through the formation of hybrid, double stranded RNA molecules. The down regulation of phytoene desaturase in plants transfected with TTO1A/PDS+ may be caused by direct interference during the translation of mRNA into protein or by duplexes formed between mRNA and viral-derived negative strand RNA.

**Example 15**

**Analysis of PDS mRNA in Nicotina Cells Producing Tomato PDS**

**Derived Specific Anti-sense RNA**

Reverse Transcriptase PCR experiments measuring the presence or absence of detectable PDS mRNA transcripts in *N. benthamiana* cells

containing TT01/PDS- (producing PDS anti-sense RNA) were performed.

RNA was isolated from transfected plants by the method of Gailiano *et al.*

The primers used to detect TT01/*L. esculentum* were

5' TAATCGATGATGATTGGAGGCTAC3' (SEQ ID NO:11) (upstream)

5' GGCACCTCAACTTATAAACCC3' (SEQ ID NO:8) (downstream). The primer used to detect *N. benthamiana* transcripts were

5' GGCACCTCAACTTATAAACCC3' (SEQ ID NO:8) (upstream) and

5' CTCCTTTAATTGTACTGCCA3' (SEQ ID NO:12) (downstream). The

10 PCR experiments were unable to detect endogenous PDS mRNA in the vector transfected plants, while the expected 452 bp anti-sense transcript could be detected. The 219 bp PDS mRNA could only be detected in the control, non-infected, *N. benthamiana* plants.

15

#### Incorporation by reference

All patents, patent applications, and publications cited are incorporated herein by reference.

20

#### Equivalents

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-described makes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

30

35

**CLAIMS**

What is claimed is:

5

1. A genetic vector capable of replication in the cytoplasm of a eukaryotic cell, the vector comprising a promoter region in functional combination with target gene inhibitor RNA encoding polynucleotide.

10

2. A vector according to claim 1, wherein the eukaryotic cell is selected from the group consisting of plant cells, yeast cells, and mammalian cells.

3. A vector according to Claim 2, wherein the eukaryotic cell is a plant cell.

15

4. A vector according to Claim 3, wherein the vector is derived from a plant RNA virus.

20

5. A vector according to claim 4, wherein the vector is derived from a single stranded RNA plant virus.

6. A vector according to claim 5 , wherein the promoter is a plant viral RNA subgenomic promoter.

25

7. A vector according to Claim 6, further comprising a second subgenomic promoter operably linked to a viral coat protein encoding polynucleotide.

30

8. A vector according to Claim 7 wherein at least one of the subgenomic promoters is derived from a tobamovirus.

35

9. A method of producing a eukaryotic cell having reduced expression of a gene of interest, the method comprising the steps of transfecting a cell with a

genetic vector according to claim 1, wherein the anti-sense RNA encoded by the anti-sense RNA encoding polynucleotide is specific for the gene of interest.

5

10. A method according to Claim 9, wherein the eukaryotic cell is selected from the group consisting of plant cells, yeast cells, and mammalian cells.

10

11. A method according to Claim 10, wherein the eukaryotic cell is a plant cell.

12. A method according to Claim 11, wherein the vector is derived from a plant RNA virus.

15

13. A method according to claim 12, wherein the vector is derived from a single stranded RNA plant virus.

20

14. A method according to claim 13, wherein the promoter is a plant viral RNA subgenomic promoter.

25

15. A method according to Claim 14, further comprising a second subgenomic promoter operably linked to a viral coat protein encoding polynucleotide.

16. A method according to Claim 15 wherein at least one of the subgenomic promoters is derived from a tobamovirus.

30

17. A eukaryotic cell produced by the method of Claim 9.

35

18. A eukaryotic cell according to Claim 17, wherein the eukaryotic cell is selected from the group consisting of plant cells, yeast cells, and mammalian cells.

5

19. A eukaryotic cell according to Claim 10, wherein the eukaryotic cell is a plant cell.

10

20. A eukaryotic cell according to Claim 19, wherein the vector is derived from a plant RNA virus.

15

21. A eukaryotic cell according to claim 20, wherein the vector is derived from a single stranded RNA plant virus.

20

22. A eukaryotic cell according to claim 21, wherein the promoter is a plant viral RNA subgenomic promoter.

25

23. A eukaryotic cell according to Claim 22, further comprising a second subgenomic promoter operably linked to a viral coat protein encoding polynucleotide.

25

24. A eukaryotic cell according to Claim 23 wherein at least one of the subgenomic promoters is derived from a tobamovirus.

25. A plant comprising a plurality of cells according to claim 19.

30

26. A plant according to Claim 25, wherein the vector is derived from a plant RNA virus.

35

27. A plant according to claim 26, wherein the vector is derived from a single stranded RNA plant virus.

28. A plant according to claim 27, wherein the promoter is a plant viral RNA subgenomic promoter.
- 5 29. A plant according to Claim 28, further comprising a second subgenomic promoter operably linked to a viral coat protein encoding polynucleotide.
- 10 30. A plant according to Claim 29 wherein at least one of the subgenomic promoters is derived from a tobamovirus.
31. A eukaryotic cell comprising a vector according to Claim 1.
- 15 32. A eukaryotic cell according to claim 31, wherein the eukaryotic cell is selected from the group consisting of plant cells, yeast cells, and mammalian cells.
- 20 33. A eukaryotic cell according to Claim 32, wherein the eukaryotic cell is a plant cell.
34. A eukaryotic cell according to Claim 33, wherein the vector is derived from a plant RNA virus.
- 25 35. A eukaryotic cell according to claim 34, wherein the vector is derived from a single stranded RNA plant virus.
- 30 36. A eukaryotic cell according to claim 35 , wherein the promoter is a plant viral RNA subgenomic promoter.
- 35 37. A eukaryotic cell according to Claim 36, further comprising a second subgenomic promoter operably linked to a viral coat protein encoding polynucleotide.

38. A eukaryotic cell according to Claim 37 wherein at least one of the subgenomic promoters is derived from a tobamovirus.

5

10

15

20

25

30

35

1/2

.tsp            XhoI            Start codon  
 GTTTAAATACGCTCGAGGTTTAAAT ATG TCT GTC GCC TTG TTA TGG GTT GTC CCT TGT GAC  
 Met Ser Val Ala Leu Leu Trp Val Val Ser Pro Cys Asp

TRANSIT PEPTIDE OF PHYTOENE SYNTHASE  
 GTC TCA AAT GGG ACA AGT TTC ATG GAA TCA GTC CGG GAG GGA AAC CGT  
 ← Val Ser Asn Gly Thr Ser Phe Met Glu Ser Val Arg Glu Gly Asn Arg




FIG.1

SUBSTITUTE SHEET (RULE 26)

2/2

PDS-Nb	ATAAACCTGACCGAGCTTCCATGCCAGTCATCTGATTGCTTGAACAG 	50
PDS-Le	ATAAACCTGACCAACTTCAATGCCAGTCATTTGATGCCATTGAACAG	50
PDS-Nb	ATTCTTCAGGAGAACATGGTCAAAAATGCCCTTTAGATGGTAACC 	100
PDS-Le	GTTTCTTCAGGAGAACATGGTCAAAAATGCCCTTTAGATGGTAATC	100
PDS-Nb	CTCCTGAGAGACTTGCATGCCATTGGAACATATTGACTCAAAGGT 	150
PDS-Le	CTCCTGAGAGACTTGCATGCCATTGGAACACATTGACTCAAAGGT	150
PDS-Nb	GGCCAAGTCAGACTAAACTCACGAATAAAAAGATCGAGCTGAATGAGGA 	200
PDS-Le	GGCCAAGTCAGACTGAACTCACGAATAAAAAGATTGACCTGAATGAGGA	200
PDS-Nb	TGGAAGTGTCAAATGTTTATACAGAATAATGCCACTACAATTAAAGGAG 	250
PDS-Le	TGGAAGTGTCAAAGACTTTATACTGAGTGACGGTAGTCAATCGAGGGAG	250
PDS-Nb	ATGCTTTGTGTTGCCACTCCAGTGGATATCTGAAGCTTCTTGCCT 	300
PDS-Le	ATGCTTTGTGTTGCCGCTCCAGTGGATATTTCAAGCTCTATTGCCT	300
PDS-Nb	GAAGACTGGAAAGAGATCCCATATTCCAAAAGTTGGAGAAGCTAGTCGG 	350
PDS-Le	GAAGACTGGAAAGAGATTCCCATATTCCAAAAGTTGGAGAAGTTAGTCGG	350
PDS-Nb	AGTCCTGTATAATGTCCATATATGTT 	380
PDS-Le	AGTACCTGTATAATGTACATATATGTT	380

FIG.2





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :	A3	(11) International Publication Number: WO 95/34668
C12N 15/83, 15/11, 15/53, 15/52, 5/10, A01H 5/00		(43) International Publication Date: 21 December 1995 (21.12.95)
(21) International Application Number:	PCT/US95/06741	(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(22) International Filing Date:	26 May 1995 (26.05.95)	
(30) Priority Data:		
260,546	16 June 1994 (16.06.94)	US
(71) Applicant: BIOSOURCE TECHNOLOGIES, INC. [US/US]; 3333 Vaca Valley Parkway, Vacaville, CA 95688 (US).		
(72) Inventors: KUMAGAI, Monto, H.; 1330 Brown Drive, Davis, CA 95616 (US). DELLA-CIOPPA, Guy, R.; 814 Derry Circle, Vacaville, CA 95688 (US). DONSON, Jonathan; 717 Alvarado Avenue #233, Davis, CA 95616 (US). HARVEY, Damon, A.; 409 Eagle Lane, Vacaville, CA 95687 (US).		
(74) Agents: HALLUIN, Albert, P. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		


## (54) Title: THE CYTOPLASMIC INHIBITION OF GENE EXPRESSION

## (57) Abstract

One aspect of the invention is to provide novel genetic constructions for the expression of inhibitory RNA in the cytoplasm of eukaryotic cells. The inhibitory RNA may be an anti-sense RNA or a co-suppressor RNA. The genetic constructions of the invention are capable of replicating in the cytoplasm of a eukaryotic cell and comprise a promoter region in functional combination with an encoding polynucleotide. The genetic constructions may be designed so as to replicate in the cytoplasm of plant cells, yeast cells, and mammalian cells. When the eukaryotic cell of interest is a plant cell, the genetic construction is preferably derived from a plant RNA virus. Plant RNA virus derived genetic constructions may employ a plant virus subgenomic promoter, including subgenomic promoters from tobamoviruses in functional combination with the RNA encoding region. Another aspect of the invention is to provide cells comprising the genetic constructions of the invention and organism comprising a plurality of such cells. Another aspect of the invention is to provide methods of reducing the expression of a gene of interest in eukaryotic cells, i.e., methods of producing eukaryotic cells exhibiting reduced levels of expression of a gene of interest. The methods of the invention comprise the step of transfecting a cell with a genetic construction of the invention in which the RNA encoding region is specific for the gene of interest. Another aspect of the invention is to provide plant cells that produce elevated levels of the carotenoid phytoene. The elevated levels of phytoene are achieved by inhibiting the expression at the enzyme phytoene desaturase using the vectors of the invention.

.  
Isp XbaI XbaI Start codon  
GTTCATTAATACCGCTTACGTTTAAAT ATG TCT GTT CCC TTG TTA TCC GTT GTT TCT CCT TGT CAC  
Met Ser Val Ala Leu Leu Trp Val Val Ser Pro Cys Asp

TRANSIT PEPTIDE OF PHYTOENE SYNTHASE  
GTC TCA AAT CGC ACA ACT TTC ATG GAA TCA GTC CGG GAG CGA AAC CGT  
Val Ser Asn Gly Thr Ser Phe Met Glu Ser Val Arg Glu Gly Asn Arg



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## INTERNATIONAL SEARCH REPORT

Inte Application No  
PCT/US 95/06741

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/83 C12N15/11 C12N15/53 C12N15/52 C12N5/10  
A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VIRUS RESEARCH, vol. 32, no. 1, 1994 pages 57-67, POWERS, A.M., ET AL. 'INTRACELLULAR IMMUNIZATION OF MOSQUITO CELLS TO LACROSSE VIRUS USING A RECOMBINANT SINDBIS VIRUS VECTOR' see the whole document --- WO,A,93 03161 (DONSON JON ;DAWSON WILLIAM O (US); GRANTHAM GEORGE L (US); TURPEN) 18 February 1993 see page 23, line 21 - line 25 see page 30, last paragraph - page 31 ---	1,2,9, 10,17, 18,31,32
X	---	1-38

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*'A' document defining the general state of the art which is not considered to be of particular relevance
- \*'E' earlier document but published on or after the international filing date
- \*'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*'O' document referring to an oral disclosure, use, exhibition or other means
- \*'P' document published prior to the international filing date but later than the priority date claimed

- \*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*'&' document member of the same patent family

2

Date of the actual completion of the international search	Date of mailing of the international search report
20 December 1995	03.01.96
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Authorized officer  Maddox, A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/06741

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 13994 (COMMW SCIENT IND RES ORG) 19 September 1991  see the whole document ---	1-6, 9-14, 17-22, 25-28, 31-36
X	EP,A,0 425 004 (AVEVE NV ;CLOVIS MATTON N V (BE); SOLVAY (BE)) 2 May 1991  see the whole document ---	1-5, 9-14, 17-22, 25-28, 31-36
P,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 92 (5). 1995. 1679-1683., KUMAGAI M H 'Cytoplasmic inhibition of carotenoid biosynthesis with virus-derived RNA.' see the whole document ---	1,2
A	WO,A,90 12107 (SALK INST BIOTECH IND) 18 October 1990 see page 13, line 30 - line 37 ---	1-38
A	NATURE, vol. 334, 14 July 1988 pages 179-182, HAYES, R.J., ET AL. 'Gene amplification and expression in plants by a replicating geminivirus vector' see page 182, last paragraph ---	1-38
A	THE PLANT JOURNAL, vol. 2, no. 3, 1992 pages 343-349, BRAMLEY, P., ET AL. 'BIOCHEMICAL CHARACTERIZATION OF TRANSGENIC TOMATO PLANTS IN WHICH CAROTENOID SYNTHESIS HAS BEEN INHIBITED THROUGH THE EXPRESSION OF ANTISENSE RNA TO PTOM5' see the whole document ---	
A	PLANT JOURNAL, vol. 4, no. 5, 1993 pages 833-840, MISAWA, N., ET AL. 'FUNCTIONAL EXPRESSION OF THE ERWINIA UREDOVORA CAROTENOID BIOSYNTHESIS GENE CRTI IN TRANSGENIC PLANTS SHOWING AN INCREASE OF BETA-CAROTENE BIOSYNTHESIS ACTIVITY AND RESISTANCE TO THE BLEACHING HERBICIDE NORFLURAZON' see the whole document ---	
2		-/-

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/US 95/06741

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,91 13078 (AMOCO CORP) 5 September 1991 see the whole document ---	
A	WO,A,91 09128 (ICI PLC) 27 June 1991 see the whole document -----	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No  
PCT/US 95/06741

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9303161	18-02-93	US-A-	5316931	31-05-94
		AU-A-	3351193	02-03-93
		CA-A-	2114636	18-02-93
		EP-A-	0596979	18-05-94
		JP-T-	7503361	13-04-95
WO-A-9113994	19-09-91	NONE		
EP-A-0425004	02-05-91	NL-A-	8902452	01-05-91
		NL-A-	9001711	01-05-91
		CA-A-	2026703	04-04-91
		JP-A-	3280883	11-12-91
WO-A-9012107	18-10-90	NONE		
WO-A-9113078	05-09-91	EP-A-	0471056	19-02-92
		JP-T-	5504686	22-07-93
WO-A-9109128	27-06-91	AU-B-	645534	20-01-94
		AU-B-	6893891	18-07-91
		EP-A-	0505405	30-09-92
		JP-T-	5502160	22-04-93
		US-A-	5304478	19-04-94



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C12N 15/83, 15/11, 15/53, 15/52, 5/10, A01H 5/00		A3	(11) International Publication Number: WO 95/34668  (43) International Publication Date: 21 December 1995 (21.12.95)
(21) International Application Number: PCT/US95/06741		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 26 May 1995 (26.05.95)			
(30) Priority Data:  260,546 16 June 1994 (16.06.94) US			
<p><b>(71) Applicant:</b> BIOSOURCE TECHNOLOGIES, INC. [US/US]; 3333 Vaca Valley Parkway, Vacaville, CA 95688 (US).</p> <p><b>(72) Inventors:</b> KUMAGAI, Monto, H.; 1330 Brown Drive, Davis, CA 95616 (US). DELLA-CIOPPA, Guy, R.; 814 Derry Circle, Vacaville, CA 95688 (US). DONSON, Jonathan; 717 Alvarado Avenue #233, Davis, CA 95616 (US). HARVEY, Damon, A.; 409 Eagle Lane, Vacaville, CA 95687 (US).</p> <p><b>(74) Agents:</b> HALLUIN, Albert, P. et al.; Pennie &amp; Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).</p>			
<p><b>Published</b>  <i>With international search report.</i>  <i>With amended claims.</i></p> <p><b>(88) Date of publication of the international search report:</b> 1 February 1996 (01.02.96)</p> <p><b>Date of publication of the amended claims:</b> 18 April 1996 (18.04.96)</p>			


**(54) Title: THE CYTOPLASMIC INHIBITION OF GENE EXPRESSION**

(57) Abstract

One aspect of the invention is to provide novel genetic constructions for the expression of inhibitory RNA in the cytoplasm of eukaryotic cells. The inhibitory RNA may be an anti-sense RNA or a co-suppressor RNA. The genetic constructions of the invention are capable of replicating in the cytoplasm of a eukaryotic cell and comprise a promoter region in functional combination with an encoding polynucleotide. The genetic constructions may be designed so as to replicate in the cytoplasm of plant cells, yeast cells, and mammalian cells. When the eukaryotic cell of interest is a plant cell, the genetic construction is preferably derived from a plant RNA virus. Plant RNA virus derived genetic constructions may employ a plant virus subgenomic promoter, including subgenomic promoters from tobamoviruses in functional combination with the RNA encoding region. Another aspect of the invention is to provide cells comprising the genetic constructions of the invention and organism comprising a plurality of such cells. Another aspect of the invention is to provide methods of reducing the expression of a gene of interest in eukaryotic cells, i.e., methods of producing eukaryotic cells exhibiting reduced levels of expression of a gene of interest. The methods of the invention comprise the step of transfected a cell with a genetic construction of the invention in which the RNA encoding region is specific for the gene of interest. Another aspect of the invention is to provide plant cells that produce elevated levels of the carotenoid phytoene. The elevated levels of phytoene are achieved by inhibiting the expression at the enzyme phytoene desaturase using the vectors of the invention.

.top XbaI Start codon  
TTTTAATACTGAGCTTTAAA ATG TCT GTT CCC TTG TTA TCC GTT GTT TCT CCT TGT GAC —  
 Met Ser Val Ala Leu Leu Ile Val Val Ser Pro Cys Asp

TRANSIT PEPTIDE OF PHYTOENE SYNTHASE  
 GTC TCA AAT CGG ACA AGT TTC ATC GAA TCA GTC CGG GAC CGA AAC CGT  
 - Val Ser Asn Glu Thr Ser Phe Met Glu Ser Val Arg Glu Gly Asn Arg



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**AMENDED CLAIMS**

[received by the International Bureau on 29 February 1996 (29.02.96);  
original claims 1-38 replaced by amended claims 1-44 (4 pages)]

desaturase is arranged in the antisense direction in relation to the promoter region which is in functional combination with the phytoene desaturase.

- 5 10. A vector according to Claim 8 wherein the target gene inhibitor RNA encoding polynucleotide is a phytoene synthase, wherein the phytoene synthase is arranged in the antisense direction in relation to the promoter region which is in functional combination with the phytoene synthase.
- 10 11. A method of producing a eukaryotic cell having reduced expression of a gene of interest, the method comprising the steps of transfecting a cell with a genetic vector according to Claim 1, wherein the anti-sense RNA encoded by the anti-sense RNA encoding polynucleotide is specific for the gene of  
15 interest.
12. A method according to Claim 11, wherein the eukaryotic cell is selected from the group consisting of plant cells, yeast cells, and mammalian cells.
- 20 13. A method according to Claim 12, wherein the eukaryotic cell is a plant cell.
- 25 14. A method according to Claim 13, wherein the vector is derived from a plant RNA virus.
15. A method according to Claim 14, wherein the vector is derived from a single stranded RNA plant virus.
- 30 16. A method according to Claim 15, wherein the promoter is a plant viral RNA subgenomic promoter.

35

17. A method according to Claim 15, further comprising a second subgenomic promoter operably linked to a viral coat protein encoding polynucleotide.
- 5 18. A method according to Claim 15, wherein at least one of the subgenomic promoters is derived from a tobamovirus.
- 10 19. A method of producing a eukaryotic cell having reduced expression of a gene of interest, the method comprising the steps of transfecting a cell with a genetic vector according to Claim 9, and then growing the transfected cell under conditions suitable for growth of the vector.
- 15 20. A method of producing a eukaryotic cell having reduced expression of a gene of interest, the method comprising the steps of transfecting a cell with a genetic vector according to Claim 10, and then growing the transfected cell under conditions suitable for growth of the vector.
- 20 21. A eukaryotic cell produced by the method of Claim 11.
- 25 22. A eukaryotic cell according to Claim 21, wherein the eukaryotic cell is selected from the group consisting of plant cells, yeast cells, and mammalian cells.
- 30 23. A eukaryotic cell according to Claim 22, wherein the eukaryotic cell is a plant cell.
24. A eukaryotic cell according to Claim 23, wherein the vector is derived from a plant RNA virus.

35

AMENDED SHEET (ARTICLE 19)

25. A eukaryotic cell according to Claim 24, wherein the vector is derived from a single stranded RNA plant virus.
- 5 26. A eukaryotic cell according to Claim 24, wherein the promoter is a plant viral RNA subgenomic promoter.
- 10 27. A eukaryotic cell according to Claim 24, further comprising a second subgenomic promoter operably linked to a viral coat protein encoding polynucleotide.
- 15 28. A eukaryotic cell according to Claim 24, wherein at least one of the subgenomic promoters is derived from a tobamovirus.
29. A plant comprising a plurality of cells according to Claim 23.
- 30 30. A plant according to Claim 29, wherein the vector is derived from a plant RNA virus.
31. A plant according to Claim 30, wherein the vector is derived from a single stranded RNA plant virus.
- 25 32. A plant according to Claim 31, wherein the promoter is a plant viral RNA subgenomic promoter.
- 30 33. A plant according to Claim 31, further comprising a second subgenomic promoter operably linked to a viral coat protein encoding polynucleotide.
34. A plant according to Claim 31, wherein at least one of the subgenomic promoters is derived from a tobamovirus.

35

35. A eukaryotic cell comprising a vector according to Claim 1.
36. A eukaryotic cell according to Claim 35, wherein the eukaryotic cell is selected from the group consisting of plant cells, yeast cells, and mammalian cells.  
5
37. A eukaryotic cell according to Claim 36, wherein the eukaryotic cell is a plant cell.  
10
38. A eukaryotic cell according to Claim 37, wherein the vector is derived from a plant RNA virus.  
15
39. A eukaryotic cell according to Claim 38, wherein the vector is derived from a single stranded RNA plant virus.  
20
40. A eukaryotic cell according to Claim 39, wherein the promoter is a plant viral RNA subgenomic promoter.  
25
41. A eukaryotic cell according to Claim 39, further comprising a second subgenomic promoter operably linked to a viral coat protein encoding polynucleotide.  
25
42. A eukaryotic cell according to Claim 39, wherein at least one of the subgenomic promoters is derived from a tobamovirus.  
30
43. A eukaryotic cell according to Claim 37 comprising a vector according to claim 9.  
35
44. A method according to Claim 37 comprising a vector according to claim 10.